Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Observational × Recurrence × Data Collection × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Neoplasms 15 Papillomavirus Infections 9 Uterine Cervical Neoplasms 6 Pancreatic Neoplasms 5 Prostatic Neoplasms 4 Ovarian Neoplasms 4 Breast Neoplasms 4 Neuroendocrine Tumors 3 Neoplasm Metastasis 3 Myasthenia Gravis 3 Multiple Myeloma 3 Melanoma 3 Lymphoma 3 Autoimmune Diseases 3 Thyroid Diseases 2 Pancreatic Cyst 2 Neuroblastoma 2 Mesothelioma, Malignant 2 Lymphoma, Non-Hodgkin 2 Lung Neoplasms 2 Leukemia, Lymphocytic, Chronic, B-Cell 2 Leukemia, Hairy Cell 2 Leukemia 2 Hematologic Neoplasms 2 Endometrial Neoplasms 2 Carcinoma, Renal Cell 2 Carcinoma, Non-Small-Cell Lung 2 COVID-19 2 Abortion, Spontaneous 2 Wilms Tumor 1

Interventions

Surgical Procedures, Operative 7 Liver Transplantation 4 Lenalidomide 4 Liquid Biopsy 3 Blood Specimen Collection 3 pomalidomide 2 gilteritinib 2 Therapeutics 2 Proteasome Inhibitors 2 Observation 2 Neoadjuvant Therapy 2 Mitomycin 2 Magnetic Resonance Spectroscopy 2 Immunotherapy, Adoptive 2 Immunoconjugates 2 High-Throughput Nucleotide Sequencing 2 DNA, Mitochondrial 2 Brentuximab Vedotin 2 Antibodies, Monoclonal 2 Antibodies, Bispecific 2 Amplified Fragment Length Polymorphism Analysis 2 trametinib 1 romidepsin 1 nedaplatin 1 lenvatinib 1 fluoroazomycin arabinoside 1 exemestane 1 elotuzumab 1 dacomitinib 1 dabrafenib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02262273 2017-03-01

OSCA

AstraZeneca

Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡